中国卒中杂志 ›› 2019, Vol. 14 ›› Issue (10): 1034-1044.DOI: 10.3969/j.issn.1673-5765.2019.10.013
中国卒中学会,中国卒中学会神经介入分会,中华预防医学会卒中预防与控制专业委员会介入学组
收稿日期:
2019-10-10
出版日期:
2019-10-20
发布日期:
2019-10-20
通讯作者:
缪中荣 zhongrongm@163.com
王拥军 yongjunwang111@aliyun.com
Received:
2019-10-10
Online:
2019-10-20
Published:
2019-10-20
中国卒中学会,中国卒中学会神经介入分会,中华预防医学会卒中预防与控制专业委员会介入学组. 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志, 2019, 14(10): 1034-1044.
Chinese Stroke Association,Chinese Interventional Neuroradiology Society,Intervention Group of Committee of Stroke Prevention and Control of Chinese Preventive Medicine Association. Chineses Experts Consensus on Clinical Application of Tirofiban in Atherosclerotic Cerebrovascular Diseases[J]. Chinese Journal of Stroke, 2019, 14(10): 1034-1044.
[1] DORNBOS D 3rd,KATZ J S,YOUSSEF P,et al.Glycoprotein Ⅱb/Ⅲa inhibitors in prevention andrescue treatment of thromboembolic complicationsduring endovascular embolization of intracranialaneurysms[J]. Neurosurgery,2018,82(3):268-277.[2] VAN'T HOF A W J,TEN BERG J,HEESTERMANS T,et al. Prehospital initiation oftirofiban in patients with ST-elevation myocardialinfarction undergoing primary angioplasty(On-TIME 2):a multicentre,double-blind,randomisedcontrolled trial[J]. The Lancet,2008,372(9638):537-546.[3] DE LUCA G,NAVARESE E,MARINO P. Riskprofile and benefits from GP Ⅱb-Ⅲa inhibitorsamong patients with ST-segment elevationmyocardial infarction treated with primaryangioplasty:a meta-regression analysis ofrandomized trials[J]. Eur Heart J,2009,30(22):2705-2713.[4] TEN BERG J M,VAN 'T HOF A W,DILL T,etal. Effect of early,pre-hospital initiation of highbolus dose tirofiban in patients with ST-segmentelevation myocardial infarction on short- and longtermclinical outcome[J]. J Am Coll Cardiol,2010,55(22):2446-2455.[5] AKPEK M,SAHIN O,SARLI B,et al. Acuteeffects of intracoronary tirofiban on no-reflowphenomena in patients with ST-segment elevated myocardial infarction undergoing primarypercutaneous coronary intervention[J]. Angiology,2015,66(6):560-567.[6] WANG H L, XING S Y, DONG P S,et al. Safety andefficacy of intracoronary tirofiban administrationin patients with serious thrombus burden andST-elevation myocardial infarction undergoingpercutaneous coronary intervention[J]. Eur Rev MedPharmacol Sci,2014,18(23):3690-3695.[7] 徐立,杨新春,王乐丰,等. 提前应用替罗非班对急性ST段抬高心肌梗死患者急诊介入治疗疗效的影响[J]. 中华心血管病杂志,2006,34(11):983-986.[8] DE LUCA G,BELLANDI F,HUBER K,et al.Early glycoprotein Ⅱb-Ⅲa inhibitors in primaryangioplasty-abciximab long-term results(EGYPTALT)cooperation:individual patient's data metaanalysis[J]. J Thromb Haemost,2011,9(12):2361-2370.[9] ROFFI M,CHEW D P,MUKHERJEE D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acutecoronary syndromes. Gradient of benefit related tothe revascularization strategy[J]. Eur Heart J,2002,23(18):1441-1448.[10] 张优,高传玉,朱中玉,等. 中高危非ST段抬高型急性冠状动脉综合征患者成功介入治疗后即刻应用替罗非班的疗效和安全性[J]. 中华心血管病杂志,2013,41(9):731-735.[11] GIUGLIANO R P,WHITE J A,BODE C,et al.Early versus delayed,provisional eptifibatide inacute coronary syndromes[J]. N Engl J Med,2009,360(21):2176-2190.[12] NEUMANN F J,SOUSA-UVA M,AHLSSON A,et al. 2018 ESC/EACTS guidelines on myocardialrevascularization[J]. Eur Heart J,2019,40(2):87-165.[13] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志,2019,47(10):766-783.[14] 国家卫生计生委合理用药专家委员会,中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版),2019,11(1):44-65.[15] WANG P,WANG Y,ZHAO X,et al. Inhospitalmedical complications associated withstroke recurrence after initial ischemic stroke:aprospective cohort study from the China NationalStroke Registry[J/OL]. Medicine(Baltimore),2016,95(37):e4929. https://doi.org/10.1097/MD.0000000000004929.[16] PAN Y,ELM J J,LI H,et al. Outcomes associatedwith clopidogrel-aspirin use in minor stroke ortransient ischemic attack:a pooled analysis ofClopidogrel in High-risk Patients with Acute NondisablingCerebrovascular Events(CHANCE)andPlatelet-Oriented Inhibition in New TIA andMinor Ischemic Stroke(POINT)trials[J/OL].JAMA Neurol,2019. https://doi.org/10.1001/jamaneurol.2019.2531.[17] 刘丽萍,陈玮琪,段婉莹,等. 中国脑血管病临床管理指南(节选版)——缺血性脑血管病临床管理[J].中国卒中杂志,2019,14(7):709-726.[18] SAQQUR M,MOLINA CA,SALAM A,et al.Clinical deterioration after intravenous recombinanttissue plasminogen activator treatment:a multicentertranscranial Doppler study[J]. Stroke,2007,38(1):69-74.[19] 中国卒中学会,中国卒中学会神经介入分会,中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2018[J]. 中国卒中杂志,2018,13(7):706-729.[20] PEERLINCK K,DE LEPELEIRE I,GOLDBERG M,et al. MK-383(L-700,462),a selective nonpeptideplatelet glycoprotein Ⅱb/Ⅲa antagonist,is active inman[J]. Circulation,1993,88(4 Pt 1):1512-1517.[21] PHILLIPS D R,CHARO I F,PARISE L V,etal. The platelet membrane glycoprotein IIb-IIIacomplex[J]. Blood,1988,71(4):831-843.[22] SCHWARZ M,MEADE G,STOLL P,et al.Conformation-specific blockade of the integrinGPⅡb/Ⅲa:a novel antiplatelet strategy thatselectively targets activated platelets[J]. Circ Res,2006,99(1):25-33.[23] COLLER B S. Anti-GPⅡb/Ⅲa drugs:currentstrategies and future directions[J]. Thromb Haemost,2001,86(1):427-443.[24] SIEBLER M,HENNERICI M G,SCHNEIDER D,et al. Safety of Tirofiban in acute Ischemic Stroke:the SaTIS trial[J]. Stroke,2011,42(9):2388-2392.[25] CHENG Z,GENG X,GAO J,et al. Intravenousadministration of standard dose tirofiban aftermechanical arterial recanalization is safe andrelatively effective in acute ischemic stroke[J]. AgingDis,2019,10(5):1049-1057.[26] KANG H S,KWON B J,ROH H G,et al. Intraarterialtirofiban infusion for thromboembolismduring endovascular treatment of intracranialaneurysms[J]. Neurosurgery,2008,63(2):230-237;discussion 237-238.[27] ZHANG Y,ZHANG Q Q,FU C,et al. Clinicalefficacy of tirofiban combined with a Solitairestent in treating acute ischemic stroke[J/OL]. Braz J Med Biol Res,2019,52(10):e8396. https://doi.org/10.1590/1414-431X20198396.[28] JUNGHANS U,SEITZ R J,AULICH A,et al.Bleeding risk of tirofiban,a nonpeptide GPⅡb/Ⅲaplatelet receptor antagonist in progressive stroke:anopen pilot study[J]. Cerebrovasc Dis,2001,12(4):308-312.[29] PHILIPPS J,THOMALLA G,GLAHN J,et al.Treatment of progressive stroke with tirofiban--experience in 35 patients[J]. Cerebrovasc Dis,2009,28(5):435-438.[30] TORGANO G,ZECCA B,MONZANI V,etal. Effect of intravenous tirofiban and aspirin inreducing short-term and long-term neurologic deficitin patients with ischemic stroke:a double-blindrandomized trial[J]. Cerebrovasc Dis,2010,29(3):275-281.[31] LI W,LIN L,ZHANG M,et al. Safety andpreliminary efficacy of early tirofiban treatment afteralteplase in acute ischemic stroke patients[J]. Stroke,2016,47(10):2649-2651.[32] SEITZ R J,MEISEL S,MOLL M,et al. The effectof combined thrombolysis with rtPA and tirofiban onischemic brain lesions[J]. Neurology,2004,62(11):2110-2112.[33] STRAUB S,JUNGHANS U,JOVANOVIC V,etal. Systemic thrombolysis with recombinant tissueplasminogen activator and tirofiban in acute middlecerebral artery occlusion[J]. Stroke,2004,35(3):705-709.[34] WU C,SUN C,WANG L,et al. Low-dose tirofibantreatment improves neurological deteriorationoutcome after intravenous thrombolysis[J]. Stroke,2019,50(12):3481-3487.[35] LIU J,SHI Q,SUN Y,et al. Efficacy of tirofibanadministered at different time points afterintravenous thrombolytic therapy with alteplasein patients with acute ischemic stroke[J]. J StrokeCerebrovasc Dis,2019,28(4):1126-1132.[36] MANGIAFICO S,CELLERINI M,NENCINIP,et al. Intravenous glycoprotein Ⅱb/Ⅲa inhibitor(tirofiban)followed by intra-arterial urokinase andmechanical thrombolysis in stroke[J]. AJNR Am JNeuroradiol,2005,26(10):2595-2601.[37] IHN Y K, SUNG J H, KIM B S. Intravenousglycoprotein iibiiia inhibitor(tirofiban)followed bylow-dose intra-arterial urokinase and mechanicalthrombolysis for the treatment of acute stroke[J].Neuroradiol J,2011,24(6):907-913.[38] 冯学问,陈智才,钟根龙,等. 急性缺血性卒中患者血管内治疗后应用替罗非班的安全性及预后分析[J].浙江大学学报(医学版),2017,46(4):397-404.[39] ZHAO W,CHE R,SHANG S,et al. Low-dosetirofiban improves functional outcome in acuteischemic stroke patients treated with endovascularthrombectomy[J]. Stroke,2017,48(12):3289-3294.[40] 中华医学会神经病学分会,中华医学会神经病学分会神经血管介入协作组,急性缺血性卒中介入诊疗指南撰写组. 中国急性缺血性卒中早期血管内介入诊疗指南[J]. 中华神经科杂志,2015,48(5):356-361.[41] KANG D H,KIM Y W,HWANG Y H,et al. Instantreocclusion following mechanical thrombectomy ofin situ thromboocclusion and the role of low-doseintra-arterial tirofiban[J]. Cerebrovasc Dis,2014,37(5):350-355.[42] ZHAO H,ZHANG J,GU D,et al. Tirofibanfacilitates the reperfusion process duringendovascular thrombectomy in ICAS[J]. Exp TherMed,2017,14(4):3314-3318.[43] SEO J H,JEONG H W,KIM S T,et al. Adjuvanttirofiban injection through deployed Solitairestent as a rescue technique after failed mechanicalthrombectomy in acute stroke[J]. Neurointervention,2015,10(1):22-27.[44] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组,中华医学会神经病学分会神经血管介入协作组. 中国缺血性脑血管病血管内介入诊疗指南2015[J]. 中华神经科杂志,2015,48(10):830-837.[45] 症状性颅内动脉粥样硬化性狭窄血管内治疗专家共识组. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识[J]. 中华内科杂志,2013,52(3):371-375.[46] 王育斌,刘佩军. 替罗非班在颅内动脉狭窄支架置入术中的应用[J]. 湖北科技学院学报(医学版),2012,26(5):388-391.[47] ZAHN R,ISCHINGER T,HOCHADEL M,et al.Glycoprotein Ⅱb/Ⅲa antagonists during carotidartery stenting:results from the carotid arterystenting(CAS)registry of the ArbeitsgemeinschaftLeitende Kardiologische Krankenhausarzte(ALKK)[J]. Clin Res Cardiol,2007,96(10):730-737.[48] VAN DELLEN D,TIIVAS C A,JARVI K,et al.Transcranial Doppler ultrasonography-directedintravenous glycoprotein Ⅱb/Ⅲa receptor antagonisttherapy to control transient cerebral microembolibefore and after carotid endarterectomy[J]. Br J Surg,2008,95(6):709-713.[49] WHOLEY M H,WHOLEY M H,ELES G,et al.Evaluation of glycoprotein Ⅱb/Ⅲa inhibitors incarotid angioplasty and stenting[J]. J Endovasc Ther,2003,10(1):33-41. [50] BRINJIKJI W,MORALES-VALERO S F,MURADM H,et al. Rescue treatment of thromboemboliccomplications during endovascular treatment ofcerebral aneurysms:a meta-analysis[J]. AJNR Am JNeuroradiol,2015,36(1):121-125.[51] JEON J S,SHEEN S H,HWANG G,etal. Intraarterial tirofiban thrombolysis forthromboembolisms during coil embolization forruptured intracranial aneurysms[J]. J CerebrovascEndovasc Neurosurg,2012,14(1):5-10.[52] CHO Y D,LEE J Y,SEO J H,et al. Intra-arterialtirofiban infusion for thromboembolic complicationduring coil embolization of ruptured intracranialaneurysms[J]. Eur J Radiol,2012,81(10):2833-2838.[53] 田红岸,赵卫,易根发. 动脉灌注替罗非班在处理颅内动脉瘤栓塞术中急性血栓栓塞的研究[J]. 介入放射学杂志,2012,21(9):718-721.[54] 冯雷,冯光,陈剑,等. 替罗非班联合尿激酶治疗破裂动脉瘤弹簧圈栓塞过程中急性血栓形成[J]. 中华神经医学杂志,2013,12(5):490-493.[55] 梁晓东,王子亮,李天晓,等. 替罗非班在颅内破裂动脉瘤介入治疗术中预防性应用研究[J]. 介入放射学杂志,2015,24(12):1034-1038.[56] 丁明祥,刘俊秀,谢兵,等. 替罗非班在颅内动脉瘤栓塞术中急性血栓形成的应用[J]. 中国微侵袭神经外科杂志,2017,22(3):101-104.[57] 金二亮,祝源,杨李,等. 替罗非班在颅内动脉瘤支架辅助栓塞术中抗血小板聚集的临床研究[J]. 中国神经外科杂志,2017,33(4):349-353.[58] 牟汝涛,刘一之,倪才方,等. 替罗非班在支架辅助颅内动脉瘤栓塞中的安全性及有效性[J]. 中国介入影像与治疗学,2017,14(3):129-133.[59] 陆新宇,李巧玉,陈波. 替罗非班治疗支架辅助弹簧圈栓塞动脉瘤术中急性血栓形成[J]. 国际神经病学神经外科学杂志,2018,45(1):22-24.[60] LIANG X D,WANG Z L,LI T X,et al. Safety andefficacy of a new prophylactic tirofiban protocolwithout oral intraoperative antiplatelet therapy forendovascular treatment of ruptured intracranialaneurysms[J]. J Neurointerv Surg,2016,8(11):1148-1153.[61] CHALOUHI N,JABBOUR P,KUNG D,et al.Safety and efficacy of tirofiban in stent-assistedcoil embolization of intracranial aneurysms[J].Neurosurgery,2012,71(3):710-714;discussion714.[62] LIMAYE K,ZANATY M,HUDSON J,et al.The safety and efficacy of continuous tirofiban asa monoantiplatelet therapy in the management ofruptured aneurysms treated using stent-assistedcoiling or flow diversion and requiring ventriculardrainage[J/OL]. Neurosurgery,2019,85(6):E1037-E1042. https://doi.org/10.1093/neuros/nyz226.[63] TCHENG J E. Clinical challenges of plateletglycoprotein Ⅱb/Ⅲa receptor inhibitor therapy:bleeding,reversal,thrombocytopenia,andretreatment[J]. Am Heart J,2000,139(2 Pt 2):S38-45.[64] LI J,YU S,QIAN D,et al. Bivalirudin anticoagulanttherapy with or without platelet glycoproteinⅡb/Ⅲa inhibitors during transcatheter coronaryinterventional procedures:a meta-analysis[J/OL].Medicine(Baltimore),2015,94(32):e1067.https://doi.org/10.1097/MD.0000000000001067.[65] 吕宪民,陈丽丽,曹亦宾,等. 替罗非班治疗进展性卒中的疗效研究[J]. 中国全科医学,2010,13(30):3376-3377.[66] 杨勇. 盐酸替罗非班联合低分子肝素治疗短暂性脑缺血发作的临床疗效[J]. 中国老年学杂志,2014,34(19):5578-5579.[67] HUYNH T,THEROUX P,SNAPINN S,et al.Effect of platelet glycoprotein Ⅱb/Ⅲa receptorblockade with tirofiban on adverse cardiac eventsin women with unstable angina/non-ST-elevationmyocardial infarction(PRISM-PLUS Study)[J]. AmHeart J,2003,146(4):668-673.[68] 董蔚,陈韵岱,钱庚,等. 国产替罗非班在急性冠状动脉综合征应用注册研究[J]. 中华科杂志,2013,52(10):815-818.[69] 李晓烨,蔡映云,吕迁洲. 肝素与替罗非班导致的血小板减少的鉴别[J]. 上海医药,2015,36(9):75-76.[70] 刘晓丽,彭萍安,程宇婧. 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在冠状动脉粥样硬化性心脏病治疗的中国专家共识(2016)[J]. 心肺血管病杂志,2016,35(12):923-932. |
[1] | 吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371. |
[2] | 伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170. |
[3] | 王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177. |
[4] | 崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188. |
[5] | 刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208. |
[6] | 徐莹鑫, 张爽, 周晓梅, 袁景林, 赵留庄, 杨海华. 非狭窄性颈动脉斑块与前循环不明原因栓塞性卒中的相关性研究 [J]. 中国卒中杂志, 2022, 17(11): 1233-1237. |
[7] | 程实, 李静, 郭军平, 胡爱香, 于鑫玮, 韩玮, 梁瑛, 张越巍, 冀瑞俊. 急性卒中患者住院期间感染的临床特征及危险因素分析[J]. 中国卒中杂志, 2022, 17(10): 1065-1070. |
[8] | 向薇, 徐璐瑶, 张曼曼, 魏红春, 梁志刚. 缺血性卒中急性期磁敏感加权成像不对称突出静脉征的发生率及影响因素分析[J]. 中国卒中杂志, 2022, 17(10): 1097-1102. |
[9] | 赵永瑞, 刘展会. 弥散张量成像在缺血性卒中患者运动功能预后评估中的研究进展[J]. 中国卒中杂志, 2022, 17(10): 1114-1119. |
[10] | 张伯煜, 郭玉成, 崔玉霞, 李英丽, 吕雨梅. 急性缺血性卒中患者就医行为决策现状及影响因素研究进展[J]. 中国卒中杂志, 2022, 17(10): 1127-1132. |
[11] | 吴亭亭, 刘亚飞, 闫世曦, 武一平, 张忠波, 张邯菲, 房娉平. “互联网+”在急性缺血性卒中救治中的应用进展[J]. 中国卒中杂志, 2022, 17(10): 1133-1138. |
[12] | 徐蔚海, 李顺, 程安琪. 青年卒中的诊治:勿过激[J]. 中国卒中杂志, 2022, 17(09): 915-918. |
[13] | 张一歌, 张婉, 张璐阳, 王鑫, 丁澜, 王玉莹, 裴璐璐, 方慧, 许予明, 宋波. 责任动脉闭塞与夹层相关缺血性卒中复发的相关性分析[J]. 中国卒中杂志, 2022, 17(09): 932-936. |
[14] | 吕微, 王安心, 田雪, 张晓丽, 许玉园, 孟霞. 心血宁胶囊对伴高同型半胱氨酸水平缺血性卒中患者短期功能预后的影响[J]. 中国卒中杂志, 2022, 17(09): 972-976. |
[15] | 张心邈, 潘岳松, 向祥龙, 王拥军, 孟霞. 早期临床路径干预改善卒中医疗服务质量关键绩效指标研究[J]. 中国卒中杂志, 2022, 17(09): 977-984. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||